Design and Optimisation of Bioactive Cyclic Peptides: Generation of a Down-Regulator of TNF Secretion

  title={Design and Optimisation of Bioactive Cyclic Peptides: Generation of a Down-Regulator of TNF Secretion},
  author={Roger New and G. S. Bansal and Malgorzata Dryjska and Michal Bogus and Patricia Green and Marc Feldmann and Fionula M. Brennan},
  pages={21529 - 21540}
Although strong binding interactions between protein receptor and ligand do not require the participation of a large number of amino acids in either site, short peptide chains are generally poor at recreating the types of protein-protein interactions which take place during cell recognition and signalling process, probably because their flexible backbones prevent the side chains from forming sufficiently rigid and stable epitopes, which can take part in binding with the desired strength and… 

Figures from this paper

Efficacy of Bioactive Cyclic Peptides in Rheumatoid Arthritis: Translation from In Vitro to In Vivo Models
Research using the CAIA animal model for rheumatoid arthritis shows that the peptides identified are indeed able to impact on inflammation of joints, induced in vivo, and suggests that these peptides are effective at a dose which could be viable in man, and at which no adverse side effects are evident in the short term.
A Global Review on Short Peptides: Frontiers and Perspectives †
The SWOT analysis of short peptides, their relevance in therapies of diverse diseases, improvements in (bio)synthesis platforms, advanced nano-supramolecular technologies, aptamers, altered peptide ligands and in silico methodologies to overcome peptide limitations, modern smart bio-functional materials, vaccines, and drug/gene-targeted delivery systems are discussed.
Binding Interactions of Peptide Aptamers
The interaction of a model cyclic decamer with a series of linear peptide constructs was compared with that of a linear peptides with the same sequence, showing that the cyclic configuration does confer benefits by increasing the strength of binding.
Serum Metabonomics Reveals Key Metabolites in Different Types of Childhood Short Stature
A systematic investigation using the metabonomics method and studied the correlation between the three groups, namely, the control, idiopathic short stature (ISS), and short stature due to growth hormone deficiency (GHD), observed that three pathways were significantly enriched in childhood SS and reported that two short peptides might play a significant role in Childhood SS.


Recent progress towards pharmaceutical applications of disulfide-rich cyclic peptides.
A range of recent studies from the laboratory focusing on the development of novel synthetic strategies and the delineation of structure-activity relationships provide much encouragement for continuing efforts to develop peptides as drugs.
Binding of flexible and constrained ligands to the Grb2 SH2 domain: structural effects of ligand preorganization.
Overall, it appears that there are more variations in the three-dimensional structure of the protein and the ligand in complexes of the constrained ligands than in those of their more flexible counterparts.
Thermodynamic and Structural Effects of Macrocyclization as a Constraining Method in Protein-Ligand Interactions.
The thermodynamic and structural effects of macrocyclization as a tactic for stabilizing the biologically-active conformation of Grb2 SH2 binding peptides were investigated using isothermal titration calorimetry and x-ray crystallography to highlight the difficulties associated with correlating energetics and structure in protein-ligand interactions.
Flexible or fixed: a comparative review of linear and cyclic cancer-targeting peptides.
Although cyclization does not necessarily improve the cancer-targeting properties of linear analogues, cyclic peptides may obtain properties that allow them to be used for additional applications, and this review aims to convey the advantages and limitations of cyclic cancer- targeting peptides.
Use of Mixed Micelles for Presentation of Building Blocks in a New Combinatorial Discovery Methodology: Proof-of-Concept Studies
A new method of combinatorial screening in which building blocks, instead of being linked together chemically, are placed on the surface of nanoparticles, so libraries comprised of many structures can be prepared rapidly, with large quantities of material available for testing.
Conformational constraint in protein ligand design and the inconsistency of binding entropy.
Three modified cyclic peptides are examined, along with multiple versions of their linear control analogs, and their thermodynamic parameters when binding the same host, the third PDZ domain of the mammalian postsynaptic density-95 (PSD-95) protein to demonstrate that the entropic relationship between a macrocyclic ligand and a linear counterpart can be a complex one that is difficult to rationalize.
Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis
  • E. Choy
  • Biology, Medicine
    Annals of the rheumatic diseases
  • 2003
The therapeutic benefit of antagonists of tumour necrosis factor alpha (TNFα) and interleukin (IL) 1 in RA provide the best evidence for the importance of cytokines in mediating synovitis.
Recent advances in neutralizing the IL-6 pathway in arthritis
  • C. Malemud
  • Biology, Medicine
    Open access rheumatology : research and reviews
  • 2009
Levels of serum and/or SF IL-6 cytokine protein superfamily members, adiponectin, oncostatin M, pre-B-cell colony enhancing factor/visfatin and leukemia inhibitory factor are elevated in RA, and additional studies will be required to determine if anti-IL-6 trans-signaling inhibition strategies with tocilizumab or recombinant soluble IL- 6R reduce the level of these cytokines.
Evidence that cytokines play a role in rheumatoid arthritis.
This Review discusses the biologic contribution and therapeutic potential of the major cytokine families to RA pathology, focusing on molecules contained within the TNF-alpha, IL-1,IL-6, Il-23, and IL-2 families.
Targeting of Interleukin-6 for the Treatment of Rheumatoid Arthritis: A Review and Update
Clinical studies can be expected to identify RA patients who should be treated with tocilizumab as a first-line biologic and indicate that therapies targeting IL-6 will be widely applicable to the treatment of various intractable immune-mediated diseases.